A novel two-step transcriptional activation system for gene therapy directed toward epithelial cells

Molecular Cancer Therapeutics

Volumn 8, Issue 12, 2009, Pages 3244-3254

  Arendt, Maja L ^a   Nasir, Lubna ^a   Morgan, Iain M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAL4 VP16 PROTEIN; GLYCOPROTEIN E2; HYBRID PROTEIN; PROTEIN VP16; RNA; RNA DIRECTED DNA POLYMERASE; TELOMERASE; TRANSCRIPTION FACTOR GAL4; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VP16 E2 FUSION PROTEIN;

ARTICLE; CANCER CELL DESTRUCTION; CONTROLLED STUDY; DNA BINDING MOTIF; DNA FLANKING REGION; DNA PROTEIN COMPLEX; EMBRYO; EPITHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENE TARGETING; HUMAN; HUMAN CELL; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN DOMAIN; SEQUENCE ANALYSIS; TARGET CELL; TATA BOX; TRANSCRIPTION INITIATION;

BINDING SITES; BOVINE PAPILLOMAVIRUS 1; CELL LINE; CELL LINE, TUMOR; DNA-BINDING PROTEINS; EPITHELIAL CELLS; GENE THERAPY; HUMANS; PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS; RNA; TELOMERASE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; VIRAL PROTEINS;

EID: 73149098714     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0543     Document Type: Article

References (26)

1. Lo HW, Day CP, Hung MC. Cancer-specific gene therapy. Adv Genet 2005;54:235-55.
2. Perlman D, Hopper JE. Constitutive synthesis of the GAL4 protein, a galactose pathway regulator in Saccharomyces cerevisiae. Cell 1979;16:89-95.
3. Sadowski I, Ma J, Triezenberg S, Ptashne M. GAL4-VP16 is an unusually potent transcriptional activator. Nature 1988;335:563-4.
4. Iyer M, Wu L, Carey M, Wang Y, Smallwood A, Gambhir SS. Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci U S A 2001;98:14595-600.
5. Iyer M, Salazar FB, Lewis X, et al. Non-invasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy. Transgenic Res 2005;14:47-55.
6. Zhang L, Adams JY, Billick E, et al. Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. Mol Ther 2002;5:223-32.
7. Hattori Y, Maitani Y. Two-step transcriptional amplification-lipid-based nanoparticles using PSMA or midkine promoter for suicide gene therapy in prostate cancer. Cancer Sci 2006;97:787-98.
8. Dzojic H, Cheng WS, Essand M. Two-step amplification of the human PPT sequence provides specific gene expression in an immunocompetent murine prostate cancer model. Cancer Gene Ther 2007;14:233-40.
9. Koch PE, Guo ZS, Kagawa S, Gu J, Roth JA, Fang B. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. Mol Ther 2001;3:278-83.
10. Wang Y, Iyer M, Annala A, Wu L, Carey M, Gambhir SS. Noninvasive indirect imaging of vascular endothelial growth factor gene expression using bioluminescence imaging in living transgenic mice. Physiol Genomics 2006;24:173-80.
11. Ray S, Paulmurugan R, Patel MR, et al. Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy. Mol Ther 2008;16:1848-56.
12. Liu BH, Yang Y, Paton JF, et al. Gal4-NF-κB fusion protein augments transgene expression from neuronal promoters in the rat brain. Mol Ther 2006;14:872-82.
13. Lee M, Oh S, Ahn CH, Kim SW, Rhee BD, Ko KS. An efficient GLP-1 expression system using two-step transcription amplification. J Control Release 2006;115:316-21.
14. Fukazawa T, Maeda Y, Sladek FM, Owen-Schaub LB. Development of a cancer-targeted tissue-specific promoter system. Cancer Res 2004;64:363-69.
15. Ray S, Paulmurugan R, Hildebrandt I, et al. Novel bidirectional vector strategy for amplification of therapeutic and reporter gene expression. Hum Gene Ther 2004;15:681-90.
16. Iyer M, Salazar FB, Lewis X, et al. Noninvasive imaging of enhanced prostate-specific gene expression using a two-step transcriptional amplification-based lentivirus vector. Mol Ther 2004;10:545-52.
17. Sato M, Johnson M, Zhang L, et al. Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy. Mol Ther 2003;8:726-37.
18. Sato M, Figueiredo ML, Burton JB, et al. Configurations of a two-tiered amplified gene expression system in adenoviral vectors designed to improve the specificity of in vivo prostate cancer imaging. Gene Ther 2008;15:583-93.
19. Burton JB, Johnson M, Sato M, et al. Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat Med 2008;14:882-8.
20. Steger G, Ham J, Yaniv M. E2 proteins: modulators of papillomavirus transcription and replication. Methods Enzymol 1996;274:173-85.
21. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008;8:167-79.
22. Vance KW, Campo MS, Morgan IM. An enhanced epithelial response of a papillomavirus promoter to transcriptional activators. J Biol Chem 1999;274:27839-44.
23. Vance KW, Campo MS, Morgan IM. A novel silencer element in the bovine papillomavirus type 4 promoter represses the transcriptional response to papillomavirus E2 protein. J Virol 2001;75:2829-38.
24. Plumb JA, Bilsland A, Kakani R, et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 2001;20:7797-803.
25. Penrose KJ, Garcia-Alai M, de Prat-Gay G, McBride AA. Casein kinase II phosphorylation-induced conformational switch triggers degradation of the papillomavirus E2 protein. J Biol Chem 2004;279:22430-9.
26. Bilsland AE, Merron A, Vassaux G, Keith WN. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Cancer Res 2007;67:1299-307.